Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Dublin, Dec. 21, 2016 -- Research and Markets has announced the addition of the "Diabetic Neuropathy Drugs Price Analysis and Strategies - 2016" report to their offering.
Diabetic Neuropathy Drugs Price Analysis and Strategies 2016, provides drug pricing data and benchmarks in the global Diabetic Neuropathy market.
The research answers the following questions:
- What are the key drugs marketed for Diabetic Neuropathy and their clinical attributes? How are they positioned in the Global Diabetic Neuropathy market?
- What are the unit prices and annual treatment cost for Diabetic Neuropathy therapies in different countries? What are the drug pricing trends and how are they expected to change in the future? How are the drug pricing and reimbursement landscape different by countries?
- What are the unmet needs in the global Diabetic Neuropathy drugs market? What would be the ideal pricing strategy for a new pipeline therapy for Diabetic Neuropathy?
Research Scope:
- Treatment Options - Identify key drugs marketed and prescribed for Diabetic Neuropathy including trade name, molecule name, and company
- Drugs Attributes - Find out the safety, efficacy, and risk benefit for key drugs marketed for Diabetic Neuropathy
- Market Positioning - Identify how drugs are clinically and commercially positioned in the global Diabetic Neuropathy market
- Diabetic Neuropathy Drugs Price Analysis - Find out the annual therapy cost and unit price for key drugs marketed
- Find out how the price advanced from 2012 and forecast to 2021
- Pricing & Reimbursement Landscape - Find out the pricing and reimbursement landscape
- Diabetic Neuropathy New Drug Pricing - Identify the effective pricing strategy for a new drug launch
Key Topics Covered:
1. Treatment Options
2. Drugs Clinical Attributes
3. Drugs Market Positioning
4. Drugs Price Analysis
5. Drugs Price Benchmarks
6. Drug Pricing & Reimbursement Landscape
7. Drugs Price Forecast
8. Market Unmet Needs
9. New Drug Pricing
For more information about this report visit http://www.researchandmarkets.com/research/v5fhz9/diabetic
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs , Endocrine and Metabolic Disorder Drugs
